MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm14228164

Медицинская библиотека · Journal of clinical medicine · 2025

Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?

Borcak Deniz, Yesilbag Zuhal, Ozdemir Yusuf Emre, Demir Adile Sevde, Dogdas Esra Salim, Sezen Aysegul Inci, Unlu Esra Canbolat, Senoglu Sevtap, Karaosmanoglu Hayat Kumbasar, Yasar Kadriye Kart

СтатьяПеревод пока не подготовлен

Аннотация

Background/

Objectives

The accurate evaluation of the fibrosis stage is critical for improving chronic hepatitis B (CHB) management and patient outcomes. This study aimed to compare the diagnostic accuracy of non-invasive fibrosis markers with liver biopsy for detecting significant, advanced fibrosis and cirrhosis. We further investigated the diagnostic performance of non-invasive markers according to HBeAg status to provide further insight into their clinical utility across patient subgroups.

Methods

This single-center retrospective study included 536 treatment-naive patients with CHB who underwent liver biopsy. Patients were categorized into four groups according to the fibrosis stage: "no significant fibrosis" (F0-F2), "significant fibrosis" (F3-F6), "advanced fibrosis" (F4-F6), and "cirrhosis" (F5-F6). AAR, AAPRI, APRI, API, FIB-4, GPR, and S-index were compared among these groups.

Results

In total, 536 treatment-naïve patients were analyzed (63.2% male; mean age 44.8 ± 12.9 years), of whom 25.4% were HBeAg-positive. API, FIB 4, GPR, and S-Index showed good performance (area under the curve [AUC] ≥ 0.8-0.9) in defining advanced fibrosis (≥F4), AAPRI, AAR, API, and APRI showed good performance ([AUC] < 0.700) in defining cirrhosis. The analysis showed that GPR had the highest AUC for ≥F3 (0.719) and ≥F4 (0.838), while FIB 4 had the highest AUC for cirrhosis (0.865).

Conclusions

These findings highlight the value of non-invasive markers as inexpensive and easily applicable methods for clinicians in assessing the stage of liver fibrosis. The integration of these scores into the routine monitoring of chronic hepatitis B patients is expected to expand, enhancing clinical decision-making and reducing the necessity for liver biopsies.

Для цитирования: Borcak Deniz, Yesilbag Zuhal, Ozdemir Yusuf Emre, Demir Adile Sevde, Dogdas Esra Salim, Sezen Aysegul Inci, Unlu Esra Canbolat, Senoglu Sevtap, Karaosmanoglu Hayat Kumbasar, Yasar Kadriye Kart. Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?. Journal of clinical medicine. 2025. DOI: 10.3390/jcm14228164.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.